Table S2. Incidence of all and high grades pneumonitis among different chemotherapeutic agent compared to immunotherapy in the corresponding studies.
| Pneumonitis | No. of studies | IMM (%) | CTH (%) | CTH agent |
|---|---|---|---|---|
| All grade pneumonitis | Five (Borghaei 2015, Brahmer 2015, Fehrenbacher 2016, Herbst 2016, Rittmeyer 2016) | 3.04 | 0.52 | Docetaxel |
| Two (Carbone 2017, Reck 2016) | 3.76 | 0.24 | Platinum-based CTH | |
| Rittmeyer 2016 | 1.43 | 0.00 | Dacarbazine | |
| Motzer 2016 | 3.94 | 14.61 | Everolimus | |
| High grade pneumonitis | Five (Borghaei 2015, Brahmer 2015, Fehrenbacher 2016, Herbst 2016, Rittmeyer 2016) | 1.37 | 0.17 | Docetaxel |
| Two (Carbone 2017, Reck 2016) | 1.88 | 0.24 | Platinum-based CTH | |
| Rittmeyer 2016 | 0 | 0 | Dacarbazine | |
| Motzer 2016 | 1.48 | 2.77 | Everolimus |
The remaining studies mentioned different investigator’s choice of chemotherapy. CTH, chemotherapy; IMM, immunotherapy.